<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TUBERSOL - tuberculin purified protein derivative injection, solution </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Tuberculin Purified Protein Derivative<br>(Mantoux)<br>TUBERSOL<span class="Sup">®</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">AHFS Category: 36:84</p>
<p><span class="Bold Italics">Rx only</span></p>
<p><span class="Bold">Diagnostic Antigen</span></p>
<p>(Aid in the detection of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>)</p>
<p><span class="Bold">FOR INTRADERMAL USE</span></p>
<p><span class="Bold">Polysorbate 80 Stabilized Solution of Tuberculin Purified Protein Derivative for Tuberculin Testing in Humans</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">TUBERSOL<span class="Sup">®</span>, Tuberculin Purified Protein Derivative (Mantoux) (PPD) (1) for intradermal tuberculin testing is prepared from a large Master Batch Connaught Tuberculin (CT68) (2) and is a cell-free purified protein fraction obtained from a human <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> grown on a protein-free synthetic medium and inactivated. (2) The use of a standard preparation derived from a single batch (CT68) has been adopted in order to eliminate batch to batch variation by the same manufacturer. (2) </p>
<p>TUBERSOL is a clear, colorless liquid.</p>
<a name="i8a771849-a061-4b57-8675-1a5f38af17f9"></a><table class="Noautorules" width="75%">
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<tbody class="Headless">
<tr class="Toprule"><td align="left" colspan="2">TUBERSOL contains:</td></tr>
<tr>
<td align="left">Purified protein derivative of <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>
</td>
<td align="left">5 TU per 0.1 mL</td>
</tr>
<tr>
<td align="left">Polysorbate 80</td>
<td align="left">0.0006%</td>
</tr>
<tr>
<td align="left">Phenol</td>
<td align="left">0.22% to 0.35% w/v</td>
</tr>
<tr><td align="left" colspan="2">in sterile isotonic phosphate buffered saline.</td></tr>
</tbody>
</table>
<p>Before release, each successive lot is tested for potency in comparison with the US Standard Tuberculin PPD-S. (3)</p>
<p>Independent studies conducted by the US Public Health Service in humans have determined the amount of CT68 in stabilized solution necessary (4) (5) (6) to produce bio-equivalency with Tuberculin PPD-S (in phosphate buffer without polysorbate 80) using 5 US units (TU) Tuberculin PPD-S as the standard.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="mechanism"></a><a name="section-3.1"></a><p></p>
<h2>MECHANISM OF ACTION</h2>
<p class="First">The sensitization following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with mycobacteria occurs primarily in the regional lymph nodes. Small <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> (T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) proliferate in response to the antigenic stimulus to give rise to specifically sensitized <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. After 3-8 weeks, these <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> enter the blood stream and circulate for years. (7) Subsequent restimulation of these sensitized <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with the same or a similar antigen, such as the intradermal injection of TUBERSOL, evokes a local reaction mediated by these cells. (8)</p>
<p>Characteristically, delayed hypersentitivity reactions to tuberculin begin at 5 to 6 hours, are maximal at 48 to 72 hours and subside over a period of days. The resultant immune response consists of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> due to cell infiltration and occasionally vesiculation and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>. Clinically, a delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to tuberculin is a manifestation of previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">M <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> or a variety of non-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> bacteria. In most cases sensitization is induced by natural <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> or by vaccination with BCG Vaccine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">TUBERSOL, Tuberculin Purified Protein Derivative (Mantoux), is indicated to aid diagnosis of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (TB) in persons at increased risk of developing active disease.</p>
<p>The Centers for Disease Control and Prevention (CDC) have published guidelines regarding populations that would benefit from tuberculin skin testing (TST). Current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm.</p>
<p>Previous BCG vaccination is not a contraindication to tuberculin testing. The skin-test results of BCG vaccinated persons can be used to support or exclude the diagnosis of TB <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. However, an FDA-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with BCG. (9)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> to any component of TUBERSOL or an anaphylactic or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to a previous test of tuberculin PPD is a contraindication to the use of TUBERSOL. (See <a href="#description">DESCRIPTION</a> and <a href="#howsupplied">HOW SUPPLIED</a>)</p>
<p>TUBERSOL should not be administered to:</p>
<ul class="Disc">
<li>Persons who have had a severe reaction (e.g., <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> or ulcerations) to a previous TST,</li>
<li>Persons with documented active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or a clear history of treatment for TB <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or disease, (10)</li>
<li>Persons with <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">extensive burns</span> or <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may occur following the use of TUBERSOL even in persons with no prior history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product components. (11) Epinephrine injection (1:1,000) and other appropriate agents used for the control of immediate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> must be immediately available.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>) can occur in association with administration of injectable medicines, including TUBERSOL. Procedures should be in place to avoid <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> injury and to restore cerebral perfusion following <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>GENERAL</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Diagnostic Limitations</h3>
<p class="First">False positive or false negative tuberculin skin test reactions may occur in some individuals. (See <a href="#interpretation">Interpretation of the Test</a>)</p>
<p>False positive tuberculin reaction tests occur in individuals who have been infected with other mycobacteria, including vaccination with BCG.</p>
<p>Not all infected persons will have a delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to a tuberculin test.</p>
<p>Many factors have been reported to cause a decreased ability to respond to the tuberculin test in the presence of tuberculous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (See <a href="#interpretation">Interpretation of the Test</a>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>INFORMATION FOR PATIENTS</h2>
<p class="First">Prior to administration of TUBERSOL, the patient's current health status and medical history should be reviewed. The physician should review the patient's immunization history for possible sensitivity to components of TUBERSOL.</p>
<p>The health-care provider should inform the patient of the need to return for the reading of the test. Self-reading of the test has been shown to be inaccurate and unreliable.</p>
<p>The health-care provider should give the patient a permanent personal record. In addition, it is essential that the health professional record the testing history in the permanent medical record of each patient. This permanent office record should contain the name of the product, date given, dose, manufacturer and lot number, as well as the test result in millimeters of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> (including 0 mm, if appropriate). Reporting results only as negative or positive is not satisfactory.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>DRUG INTERACTIONS</h2>
<p class="First">Reactivity to the test may be depressed or suppressed in persons who are receiving corticosteroids or immunosuppressive agents. (8)</p>
<p>Reactivity to TUBERSOL may be temporarily depressed by certain live virus vaccines (<span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, oral <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span>, <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>). If a parenteral live attenuated virus vaccine has been administered recently, tuberculin testing should be delayed for &gt;1 month after vaccination. (8) (12) (See <a href="#interpretation">Interpretation of the Test</a>)</p>
<p>When tuberculin screening is required at the same time as a <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>-containing vaccine or other parenteral live attenuated virus vaccine, simultaneous administration of TUBERSOL and the vaccine at separate sites is the preferred option.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</h2>
<p class="First">TUBERSOL has not been evaluated for its carcinogenic or mutagenic potentials or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>PREGNANCY</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3>PREGNANCY CATEGORY C</h3>
<p class="First">Animal reproduction studies have not been conducted with TUBERSOL. It is also not known whether TUBERSOL can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TUBERSOL should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>NURSING MOTHERS</h2>
<p class="First">It is not known whether TUBERSOL is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TUBERSOL is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">There is no age contraindication to tuberculin skin testing of infants. Because their immune systems are immature, many infants &lt;6 weeks of age who are infected with <span class="Italics">M</span>. <span class="Italics"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> do not react to tuberculin tests. (13) (See <a href="#interpretation">Interpretation of the Test</a>)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>GERIATRIC USE</h2>
<p class="First">Clinical studies of TUBERSOL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span> at the TUBERSOL injection site is the expected reaction for a positive skin test. (See <a href="#interpretation">Interpretation of the Test</a>)</p>
<p>The information pertaining to adverse events has been compiled from historical clinical studies and post-marketing experience with TUBERSOL.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>General disorders and administration site conditions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span>, injection site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and injection site <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</p>
<p>Injection site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or <span class="product-label-link" type="condition" conceptid="4318391" conceptname="Injection site dermatitis">injection site rash</span> (without <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>) occurring within 12 hours of testing. These reactions do not indicate TB <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">Injection site hemorrhage</span> and injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> up to three days after the administration of the test.</p>
<p>Injection site <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="4316210" conceptname="Injection site ulcer">injection site ulcer</span> or <span class="product-label-link" type="condition" conceptid="4318393" conceptname="Injection site necrosis">injection site necrosis</span> in highly sensitive persons.</p>
<p><span class="product-label-link" type="condition" conceptid="4005984" conceptname="Injection site scar">Injection site scar</span> as a result of strongly positive reactions.</p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, angiodema, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">Stridor</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Skin and subcutaneous tissue disorders</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">Presyncope</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (including <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> associated with tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> and other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-like activity) sometimes resulting in transient <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> with injury</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>REPORTING OF ADVERSE EVENTS</h2>
<p class="First">To report SUSPECTED ADVERSE REACTIONS, contact the Pharmacovigilance Department, Sanofi Pasteur Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-2463 (1-800-VACCINE) or Food and Drug Administration (FDA) MEDWATCH Program at 1-800-332-1088 and www.fda.gov/medwatch.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>DOSAGE</h2>
<p class="First">Five (5) tuberculin units (TU) per test dose of 0.1 mL is the standard strength used for intradermal (Mantoux) testing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>METHOD OF ADMINISTRATION</h2>
<p class="First"><span class="Bold">TUBERSOL is indicated for intradermal injection only. Do not inject intravenously, intramuscularly, or subcutaneously</span>. If subcutaneous injection occurs, the test cannot be interpreted.</p>
<p>Inspect for extraneous particulate matter and/or discoloration before use. If these conditions exist, do not administer the product.</p>
<p>Use a separate syringe and needle for each injection.</p>
<p>The following procedure is recommended for performing the Mantoux test:</p>
<ol class="Arabic">
<li>The preferred site of the test is the volar aspect of the forearm. Avoid areas on the skin that are red or swollen. Avoid visible veins.</li>
<li>Clean the skin site with a suitable germicide and allow the site to dry prior to injection of the antigen.</li>
<li>Administer the test dose (0.1 mL) of TUBERSOL with a 1 mL syringe calibrated in tenths and fitted with a short, one-quarter to one-half inch, 26 or 27 gauge needle.</li>
<li>Wipe the stopper of the vial with a suitable germicide and allow to dry before needle insertion. Then insert the needle gently through the stopper and draw 0.1 mL of TUBERSOL into the syringe. Avoid injection of excess air with removal of each dose so as not to over pressurize the vial and possibly cause seepage at the puncture site.</li>
<li>Insert the point of the needle into the most superficial layers of the skin with the needle bevel pointing upward and administer the dose by slow <span class="Bold">intradermal injection</span>. If the intradermal injection is performed properly, a definite <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> bleb will rise at the needle point, about 10 mm (⅜") in diameter. This bleb will disperse within minutes. Do not dress the site.</li>
<li>A drop of blood may appear at the administration site following injection. Blot the site lightly to remove the blood but avoid squeezing out the injected tuberculin test fluid.</li>
</ol>
<p>In the event of an improperly performed injection (ie, no bleb formed), repeat the test immediately at another site, at least 2 inches from the first site and circle the second injection site as an indication that this is the site to be read.</p>
<p>Inform the patient of the need to return for the reading of the test by a trained health professional. Self-reading may be inaccurate and is strongly discouraged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="interpretation"></a><a name="section-9.3"></a><p></p>
<h2>INTERPRETATION OF THE TEST</h2>
<p class="First">The skin test should be read by a trained health professional 48 to 72 hours after administration of TUBERSOL. Skin test sensitivity is indicated by <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> only; <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> should not be measured.</p>
<p>Measure the diameter of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> transversely to the long axis of the forearm and record the measurement in millimetres (including 0 mm). (8) The tip of a ballpoint pen, gently pushed at a 45° angle toward the site of injection, will stop at the edge of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>.</p>
<p>Also record presence and size (if present) of <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, although these are not used in the interpretation of the test.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3.1"></a><p></p>
<h3>Positive Reactions</h3>
<p class="First">Tuberculin reactivity may indicate latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, prior <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and/or disease with <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> and does not necessarily indicate the presence of active tuberculous disease. Persons showing positive tuberculin reactions should be considered positive by current public health guidelines and referred for further medical evaluation. (8) (10) The repeated testing of uninfected persons does not sensitize them to TUBERSOL. (7) (8) (10) (13)</p>
<p>The significance of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> measurements in diagnosing latent TB <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> must be considered in terms of the patient's history and the risk of developing active TB disease as indicated in Table 1. (10)</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Criteria for tuberculin positivity, by risk group</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Reaction ≥5 mm of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></th>
<th class="Rrule" align="center">Reaction ≥10 mm of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></th>
<th class="Rrule" align="center">Reaction ≥15 mm of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Risk of TB in patients treated with corticosteroids increases with higher dose and longer duration.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>For persons who are otherwise at low risk and are tested at the start of employment, a reaction of ≥15 mm <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> is considered positive.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">
<p class="First">HIV-positive persons</p>
<br><p>Recent contacts of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB) case patients</p>
<br><p>Fibrotic changes on chest radiograph consistent with prior TB</p>
<br><p>Patients with organ transplants and other immunosuppressed patients (receiving the equivalent of ≥15 mg/d of prednisone for 1 month or more)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
</td>
<td class="Rrule" align="left">
<p class="First">Recent immigrants (i.e., within the last 5 yrs) from high prevalence countries</p>
<br><p>Injection drug users</p>
<br><p>Residents or employees<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> of the following high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS) and homeless shelters</p>
<br><p>Mycobacteriology laboratory personnel</p>
<br><p>Persons with the following clinical conditions that place them at high risk: <span class="product-label-link" type="condition" conceptid="442125" conceptname="Pneumoconiosis due to silica">silicosis</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, some hematologic disorders (e.g., <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>), other specific malignancies (e.g., carcinoma of the head or neck and lung), <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of ≥10% of ideal body weight, gastrectomy and jejunoileal bypass</p>
<br><p>Children younger than 4 yrs of age or infants, children, and adolescents exposed to adults at high-risk</p>
</td>
<td class="Rrule" align="left">Persons with no risk factors for TB</td>
</tr></tbody>
</table>
<p>A TST conversion is defined as an increase of ≥ 10 mm of <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> within a 2-year period, regardless of age. (10)</p>
<p>The possibility should be considered that the skin test sensitivity may also be due to a previous contact with atypical mycobacteria or previous BCG vaccination. (8) (10) (13)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3.2"></a><p></p>
<h3>Negative Reactions</h3>
<p class="First">An individual who does not show a positive reaction to 5 TU on the first test, but is suspected of being TB positive, may be retested with 5 TU. (See <a href="#booster">Booster Effect and Two-Step Testing</a>) Any individual who does not show a positive reaction to an initial injection of 5 TU, or a second test with 5 TU may be considered as tuberculin negative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3.3"></a><p></p>
<h3>False Positive Reactions</h3>
<p class="First">False positive tuberculin reactions can occur in individuals who have been infected with other mycobacteria, including vaccination with BCG. (8) (13) However, a diagnosis of <span class="Italics">M<span class="Underline">.</span> <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the use of preventive therapy should be considered for any BCG-vaccinated person who has a positive TST reaction, especially if the person has been, or is, at increased risk of acquiring TB <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (See <a href="#indications">INDICATIONS AND USAGE</a>) (15) (16)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3.4"></a><p></p>
<h3>False-Negative Reactions</h3>
<p class="First">Not all infected persons will have a delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to a tuberculin test.</p>
<p>In those who are elderly or those who are being tested for the first time, reactions may develop slowly and may not peak until after 72 hours.</p>
<p>Since tuberculin sensitivity may take up to 8 weeks to develop following exposure to <span class="Italics">M. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span> (See <a href="#mechanism">Mechanism of Action</a>), persons who have a negative tuberculin test &lt;8 weeks following possible TB exposure should be retested ≥8-10 weeks following the last known or suspected exposure. (17)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3.4.1"></a><p></p>
<h4>Altered Immune Status</h4>
<p class="First">Impaired or attenuated cell mediated immunity (CMI) can potentially cause a false negative tuberculin reaction. Many factors have been reported to cause a decreased ability to respond to the tuberculin test in the presence of tuberculous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> including <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>  and HIV), live virus vaccinations (e.g., <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, oral <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span> and <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span>), overwhelming <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, other <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>, <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, metabolic derangements, low protein states, diseases affecting lymphoid organs, drugs (corticosteroids and many other immunosuppressive agents), and malignancy or stress. (8) (18) (19) A TST should be deferred for patients with major <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> or live-virus vaccination in the past month. Persons with the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> may be tuberculin tested.</p>
<p>Because TST results in HIV-infected individuals are less reliable as CD4 counts decline, screening should be completed as early as possible after HIV-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs. (19)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="booster"></a><a name="section-9.4"></a><p></p>
<h2>BOOSTER EFFECT AND TWO-STEP TESTING</h2>
<p class="First">If tuberculin testing will be conducted at regular intervals, for instance among health-care workers or prison workers, two-step testing should be performed as a baseline to avoid interpreting a booster effect as a tuberculin conversion. If the first test showed either no reaction or a small reaction, the second test should be performed one to four weeks later. Both tests should be read and recorded at 48 to 72 hours. Patients with a second tuberculin test (booster) response of ≥ 10 mm should be considered to have experienced past TB <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (15) (20)</p>
<p>Persons who do not boost when given repeat tests at one week, but whose tuberculin reactions change to positive after one year, should be considered to have newly acquired <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and managed accordingly. (7)</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="howsupplied"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">TUBERSOL, Tuberculin Purified Protein Derivative (Mantoux), bioequivalent to 5 US units (TU) PPD-S per test dose (0.1 mL) is supplied in:</p>
<p>10-test vial, 1 mL. package of 1 vial, NDC No. 54868-2972-1</p>
<p>50-test vial, 5 mL. <br></p>
<p>The stopper of the vial for this product does not contain natural latex rubber.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 2° to 8°C (35° to 46°F). (21) <span class="Bold">Do not freeze.</span> Discard product if exposed to freezing.</p>
<p><span class="Bold">Protect from light.</span> Tuberculin PPD solutions can be adversely affected by exposure to light. The product should be stored in the dark except when doses are actually being withdrawn from the vial. (22)</p>
<p><span class="Bold">A vial of TUBERSOL which has been entered and in use for 30 days should be discarded.</span> (23)</p>
<p>Do not use after expiration date.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1</dt>
<dd>Landi S. Preparation, purification, and stability of tuberculin. Appl Microbiol 1963;11:408-412.</dd>
<dt>2</dt>
<dd>Landi S, et al. Preparation and characterization of a large batch of tuberculin purified protein derivative (PPD-CT68). Ann Scalvo.1980;22:889-907.</dd>
<dt>3</dt>
<dd>US Code of Federal Regulations, Title 21, Part 610, Subpart C - Standard preparations and limits of potency.</dd>
<dt>4</dt>
<dd>Landi S, et al. Adsorption of tuberculin PPD to glass and plastic surfaces. Bull. WHO 1966;35:593-602.</dd>
<dt>5</dt>
<dd>Landi S, et al. Disparity of potency between stabilized and nonstabilized dilute tuberculin solutions. Am Rev Respir Dis 1971;104:385-393.</dd>
<dt>6</dt>
<dd>Landi S, et al. Stability of dilute solutions of tuberculin purified protein derivative. Tubercle 1978;59:121-133.</dd>
<dt>7</dt>
<dd>Menzies D. Interpretation of repeated tuberculin tests. Am J Respir Crit Care Med 1999;159:15-21.</dd>
<dt>8</dt>
<dd>American Thoracic Society: Diagnostic standards and classification of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in adults and children. Am J Respir Crit Care Med 2000;161:1376-1395.</dd>
<dt>9</dt>
<dd>CDC. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> - United States, 2010. MMWR 2010; 59 (RR-5):1-25.</dd>
<dt>10</dt>
<dd>CDC. Targeted tuberculin testing and treatment of latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. MMWR 2000;49(RR-6):23-5.</dd>
<dt>11</dt>
<dd>Froeschle JE, et al. <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span> after use of tuberculin skin testing. Clin Infect Dis 2002;34:e12-13.</dd>
<dt>12</dt>
<dd>Brickman HF, et al. The timing of tuberculin tests in relation to immunization with live viral vaccines. Pediatrics: 1975;55:392-396.</dd>
<dt>13</dt>
<dd>Huebner RE, et al. <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> commentary: the tuberculin skin test. Clin Infect Dis 1993;17:968-75.</dd>
<dt>14</dt>
<dd>CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP).  MMWR 2002;51(RR-2):1-35.</dd>
<dt>15</dt>
<dd>CDC. Guidelines for preventing the transmission of Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in health-care settings, 2005. MMWR 2005;54(RR-17):1-141.</dd>
<dt>16</dt>
<dd>CDC. The role of BCG vaccine in the prevention and control of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in the United States. A joint statement by the Advisory Council for the Elimination of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> and the Advisory Committee on Immunization Practices. MMWR 1996; 45(RR-4):8-9.</dd>
<dt>17</dt>
<dd>CDC. Guidelines for the Investigation of Contacts of Persons with Infectious <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span>: Recommendations from the National <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span> Controllers Association and CDC. MMWR 2005;54(RR-15):1-47.</dd>
<dt>18</dt>
<dd>Mori and Shiozawa. Suppression of tuberculin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> caused by <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Am Rev Respir Dis 1985;886-888.</dd>
<dt>19</dt>
<dd>CDC. Guidelines for prevention and treatment of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> in HIV-infected adults and adolescents. Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of Infectious Diseases Society of America. MMWR 2009;58(RR-4):1-207.</dd>
<dt>20</dt>
<dd>CDC. Prevention and control of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in correctional and detention facilities: Recommendations from the CDC. MMWR 2006;55(RR-9):1-44.</dd>
<dt>21</dt>
<dd>Landi S, et al. Stability of dilute solution of tuberculin purified protein derivative at extreme temperatures. J Biol Stand 1981;9:195-199.</dd>
<dt>22</dt>
<dd>Landi S, et al. Effect of light on tuberculin purified protein derivative solutions. Am Rev Respir Dis 1975;111:52-61.</dd>
<dt>23</dt>
<dd>Landi S, et al. Effect of oxidation on the stability of tuberculin purified protein derivative (PPD) In: International Symposium on Tuberculins and BCG Vaccine. Basel: International Association of Biological Standardization, 1983. Dev Biol Stand 1986;58:545-552.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">Sanofi Pasteur Limited</span><br>Toronto Ontario Canada</p>
<p>Distributed by:<br><span class="Bold">Sanofi Pasteur Inc</span>. 										<br>Swiftwater PA 18370 USA</p>
<p>Product Information as of<br>March 2013</p>
<p>Printed in Canada</p>
<p>R9-0313 USA</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<p class="First">Distributed by:<br>Physicians Total Care, Inc.<br>Tulsa, OK        74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL Vial Package Label</h1>
<p class="First"><span class="Bold">Tuberculin Purified<br>Protein Derivative<br>(Mantoux)</span><br>TUBERSOL<span class="Sup">®</span> 1 mL (10 Tests)<br>Test dose: 5 TU/0.1 mL ID.<br>Protect from light.<br>Discard opened<br>product after 30 days.</p>
<p><span>Rx only</span></p>
<p><span class="Bold">Sanofi Pasteur Limited</span></p>
<p>Date opened</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL Vial Carton</h1>
<p class="First"><span class="Bold"><br></span></p>
<p><span class="Bold">PPD</span></p>
<p><span class="Bold">Tuberculin Purified Protein<br>Derivative (Mantoux)<br>TUBERSOL<span class="Sup">®</span></span></p>
<p><span class="Bold">10<br>Tests</span><br>5 TU</p>
<p><span class="Bold">Tween Stabilized Solution</span></p>
<p><span>Rx only</span></p>
<p>Test dose: 5 TU/0.1 mL intradermally.</p>
<p>Bio-equivalent to 5 US units (TU) of PPD-S</p>
<p><span class="Bold">SANOFI PASTEUR</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=96d91ba3-9dfe-4420-a835-57647ea30b40&amp;name=tubersol-02.jpg"></div>
<br><div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mL Vial Package Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=96d91ba3-9dfe-4420-a835-57647ea30b40&amp;name=2972.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TUBERSOL 		
					</strong><br><span class="contentTableReg">tuberculin purified protein derivative injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-2972(NDC:49281-752)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRADERMAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tuberculin Purified Protein Derivative</strong> (Tuberculin Purified Protein Derivative) </td>
<td class="formItem">Tuberculin Purified Protein Derivative</td>
<td class="formItem">5 [iU]  in 0.1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polysorbate 80</strong></td>
<td class="formItem">0.0125 uL  in 0.1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Phenol</strong></td>
<td class="formItem">0.35 mg  in 0.1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (clear colorless) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-2972-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103941</td>
<td class="formItem">08/15/1956</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-2972)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>676d3ac0-adfe-40ef-861b-c19680ab9ba3</div>
<div>Set id: 96d91ba3-9dfe-4420-a835-57647ea30b40</div>
<div>Version: 1</div>
<div>Effective Time: 20130522</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
